Biotech veteran Oz Azam has become the CEO of Cue Biopharma. He walks us through the science behind the company's new focus in autoimmune that has him excited about the opportunity

Oct 21, 2025
1 min read

He describes CUE-401, which combines a TGF-beta breathing-mask moiety with an interleukin (IL-2) mutein, and CUE-501, a Boehringer Ingelheim partnered program which is designed to deplete B-cells by painting them and engaging with virus-specific memory T-cells.

https://vimeo.com/1129250938

Recent Posts

See All

Protagonist Therapeutics has two medicines in front of FDA right now - we discuss the expertise in peptide based drug development that has enabled them to get to this point

Cambridge, UK based Arecor uses formulation and development expertise to improve the profile of medicines - the company believes it has its own best in class insulin leveraging this

Gordian Biotechnology announced that it will be using its unique large-scale in vivo screening process to help Pfizer look for new targets against obesity

Biotech veteran Oz Azam has become the CEO of Cue Biopharma. He walks us through the science behind the company's new focus in autoimmune that has him excited about the opportunity

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight